Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
SOUTH SAN FRANCISCO, Calif., May 2, 2016 -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, will report financial results for the quarter ended March 31, 2016 after market close on Monday May, 9 2016. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Date: May 9, 2016
Time: 1:30 PM PT
Listen via Internet: http://ir.tobiratx.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=71324&k=B42CB87C
Toll-free: 1 (855) 638-8858
International: +1 (707) 294-1299
Access code: 99831682
A webcast replay will be available on the Tobira Web site for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 (855) 859-2056 for domestic callers, or +1 (404) 537-3406 for international callers, and entering reservation code 99831682.
About Tobira Therapeutics, Inc.
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and as an adjunctive therapy to standard of care in HIV. Tobira's pipeline also includes evogliptin, a selective DPP-4 inhibitor, which it plans to develop for NASH in combination with CVC. Learn more about Tobira at http://www.tobiratx.com.
Tobira(R) is a registered trademark owned by Tobira Therapeutics, Inc.
(c)2016 Tobira Therapeutics, Inc. All Rights Reserved.
CONTACT: Tobira Investor & Media Contact
Ian Clements, PhD
+1 (650) 351-5013
[email protected]
Canale Communications Media Contact
Pam Lord
+1 (619) 849-6003
[email protected]
